<DOC>
	<DOC>NCT00097487</DOC>
	<brief_summary>This study is a Phase IV, prospective, nonrandomized, community-based study of clinical outcomes in patients with metastatic breast cancer treated with Herceptin and a taxane.</brief_summary>
	<brief_title>A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Signed informed consent Available tissue for central laboratory evaluation of HER2 status Histologically confirmed, measurable or nonmeasurable but evaluable, HER2 positive metastatic breast cancer (HER2 positive is defined as 3+ staining by IHC or gene amplification by FISH, determined by the local or central laboratory) Life expectancy &gt;6 months Female, age &gt;=18 years ECOG performance status of 0, 1, or 2 Adequate bone marrow function as indicated by the following: *ANC &gt;1500/uL, *Platelet count &gt;=100,000/uL Adequate renal function, as indicated by creatinine &lt;=1.5× upper limit of normal (ULN) Adequate liver function, as indicated by bilirubin &lt;=1.5× ULN and AST or ALT &lt;2× ULN unless related to primary disease Use of an adequate means of birth control (women of childbearing potential) Initiation of Herceptin &gt;=4 weeks after beginning taxane chemotherapy Prior chemotherapy for metastatic disease Prior cumulative anthracycline dose of &gt;360 mg/m2 History of significant cardiac disease or uncontrolled arrhythmias Ejection fraction of &lt;50% or below the lower limit of normal Active infection Symptomatic or untreated brain metastases Pregnancy or lactation Concomitant malignancies or previous malignancies within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest Hypersensitivity to study medications Major organ failure or systemic disease precluding the safe administration of study medications</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2004</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>